Research
There are ongoing efforts to develop sublingual epinephrine to treat anaphylaxis. Trials of sublingual epinephrine, currently called AQST-108 (dipivefrin) and sponsored by Aquestive Therapeutics, are in phase 1 trials as of December 2021. Subcutaneous injection of the anti-IgE antibody omalizumab is being studied as a method of preventing recurrence, but it is not yet recommended. References
External links

Anaphylaxis at Curlie
National Institute for Health and Clinical Excellence. Clinical guideline 134: Anaphylaxis: assessment to confirm an anaphylactic episode and the decision to refer after emergency treatment for a suspected anaphylactic episode. London, 2011. and Anaphylaxis pathway
"Anaphylaxis". MedlinePlus. U.S. National Library of Medicine.
Basophilia on its own does not cause much complication other than those related to the primary causative condition. However, basophils can degranulate causing tissue damage, but this can be avoided with early detection and intervention. Treatment
Basophilia, as it is primarily a secondary condition, is treated by addressing the causative disease or disorder. The underlying condition will determine what treatment is appropriate. Specifically in cases of allergic reactions or associated with chronic inflammation, treating the underlying cause is critical to avoid further, potentially irreparable damage to the bodys organ systems. Common treatments to allergic reactions include cessation of utilization of the offending agent, and the administration of antihistamines. Infection-related basophilia can be remedied by utilizing antibiotics to treat the underlying causative infection, whereas neoplasm related basophilia may have a more complicated clinical course including chemotherapy and periodic phlebotomy. References


== External links ==